Human fetal cardiac progenitors: The role of stem cells and progenitors in the fetal and adult heart

Bulatović, Ivana; Månsson‐Broberg, Agneta; Sylvén, Christer; Grinnemo, Karl‐Henrik

doi:10.1016/j.bpobgyn.2015.08.008

Cited by 27 publications

(32 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No definitive explanations were found for these changes. One of the vital organs during embryo development is the heart, which starts to develop at a very early stage [28], making it vulnerable to extragenous disruptions. A chicken embryo is an established model for the study of development and various diseases, including tumor and cardiovascular diseases [29].…”

Section: Discussionmentioning

confidence: 99%

The Roles of Reactive Oxygen Species and Nitric Oxide in Perfluorooctanoic Acid-Induced Developmental Cardiotoxicity and l-Carnitine Mediated Protection

Zhao

Jiang

Wang

et al. 2017

IJMS

View full text Add to dashboard Cite

Perfluorooctanoic acid (PFOA) is an environmental contaminant that could induce developmental cardiotoxicity in a chicken embryo, which may be alleviated by l-carnitine. To explore the roles of reactive oxygen species (ROS) and nitric oxide (NO) in such changes and the potential effects of l-carnitine, fertile chicken eggs were exposed to PFOA via an air cell injection, with or without l-carnitine co-treatment. The ROS and NO levels in chicken embryo hearts were determined with electron spin resonance (ESR), and the protein levels of the nuclear factor κ-light chain-enhancer of activated B cells (NF-κB) p65 and inducible nitric oxide synthase (iNOS) in chicken embryo hearts were assessed with western blotting. The results of ESR indicated that PFOA exposure induced an elevation in the ROS levels in ED19 chicken embryo hearts and hatchling chicken hearts, while l-carnitine could alleviate such changes. Meanwhile, increased NO levels were observed in ED19 embryo hearts and hatchling hearts following PFOA exposure, while l-carnitine co-treatment exerted modulatory effects. Western blotting revealed that p65 translocation in ED19 embryo hearts and hatchling hearts was enhanced by PFOA, while l-carnitine co-treatment alleviated such changes. iNOS expression levels in ED19 embryo hearts followed the same pattern as NO levels, while a suppression of expression was observed in hatchling hearts exposed to PFOA. ROS/NF-κB p65 and iNOS/NO seem to be involved in the late stage (ED19 and post hatch) of PFOA-induced developmental cardiotoxicity in a chicken embryo. l-carnitine could exert anti-oxidant and NO modulatory effects in the developing chicken embryo hearts, which likely contribute to its cardioprotective effects.

show abstract

Section: Discussionmentioning

confidence: 99%

The Roles of Reactive Oxygen Species and Nitric Oxide in Perfluorooctanoic Acid-Induced Developmental Cardiotoxicity and l-Carnitine Mediated Protection

Zhao

Jiang

Wang

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…The human heart is one of the first organs to form and function during embryogenesis [1,2]. By the end of gestational week 3, passive oxygen diffusion becomes insufficient to support metabolism of the developing embryo [3][4][5], and thus the fetal heart becomes vital for oxygen and nutrient distribution [2].…”

Section: Introductionmentioning

confidence: 99%

The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life

Tan

Lewandowski²

2019

Fetal Diagn Ther

172

123

View full text Add to dashboard Cite

Formation of the human heart involves complex biological signals, interactions, specification of myocardial progenitor cells, and heart tube looping. To facilitate survival in the hypoxemic intrauterine environment, the fetus possesses structural, physiological, and functional cardiovascular adaptations that are fundamentally different from the neonate. At birth, upon separation from the placental circulation, the neonatal cardiovascular system takes over responsibility of vital processes for survival. The transition from the fetal to neonatal circulation is considered to be a period of intricate physiological, anatomical, and biochemical changes in the cardiovascular system. With a successful cardiopulmonary transition to the extrauterine environment, the fetal shunts are functionally modified or eliminated, enabling independent life. Investigations using medical imaging tools such as ultrasound and magnetic resonance imaging have helped to define normal and abnormal patterns of cardiac remodeling both in utero and ex utero. This has not only allowed for a better understanding of how congenital cardiac malforma-tions alter the hemodynamic transition to the extrauterine environment but also how other more common complications during pregnancy including intrauterine growth restriction, preeclampsia, and preterm delivery adversely affect offspring cardiac remodeling during this early transitional period. This review article describes key cardiac progenitors involved in embryonic heart development; the cellular, physiological, and anatomical changes during the transition from fetal to neonatal circulation; as well as the unique impact that different pregnancy complications have on cardiac remodeling.

show abstract

“…80 For cell therapeutic purpose, cardiac progenitor cells seem unsuitable and other stem cells are being investigated, such as lineage-specified cardiopoietic MSC or stem cells differentiated from embryonic stem cell (ESC) or iPSC from heart fibroblasts. 81…”

Section: Adipose-derived Stem Cells (Adsc)mentioning

confidence: 99%

Prenatal stem cell therapy for inherited diseases: Past, present, and future treatment strategies

Ekblad‐Nordberg

Walther‐Jallow

Westgren

2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Imagine the profits in quality of life that can be made by treating inherited diseases early in life, maybe even before birth! Immense cost savings can also be made by treating diseases promptly. Hence, prenatal stem cell therapy holds great promise for developing new and early-stage treatment strategies for several diseases. Successful prenatal stem cell therapy would represent a major step forward in the management of patients with hematological, metabolic, or immunological disorders. However, treatment before birth has several limitations, including ethical issues. In this review, we summarize the past, the present, and the future of prenatal stem cell therapy, which includes an overview of different stem cell types, preclinical studies, and clinical attempts treating various diseases. We also discuss the current challenges and future strategies for prenatal stem cell therapy and also new approaches, which may lead to advancement in the management of patients with severe incurable diseases. K E Y W O R D Scell therapy, inherited diseases, prenatal, stem cell, treatment strategies

show abstract

Human fetal cardiac progenitors: The role of stem cells and progenitors in the fetal and adult heart

Cited by 27 publications

References 104 publications

The Roles of Reactive Oxygen Species and Nitric Oxide in Perfluorooctanoic Acid-Induced Developmental Cardiotoxicity and l-Carnitine Mediated Protection

The Roles of Reactive Oxygen Species and Nitric Oxide in Perfluorooctanoic Acid-Induced Developmental Cardiotoxicity and l-Carnitine Mediated Protection

The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life

Prenatal stem cell therapy for inherited diseases: Past, present, and future treatment strategies

Contact Info

Product

Resources

About